Frontline Management of Atopic Dermatitis in Adults : Episode 6

Opinion

Video

March 3, 2025

The Utility of Newer Topical Therapies for Atopic Dermatitis

Author(s):

Brad P. Glick, DO, MPH,Zed Zha, MD, FAAFP

Panelists discuss how upcoming topical therapeutics for atopic dermatitis include corticosteroid-sparing treatments like topical calcineurin inhibitors (eg, tacrolimus, pimecrolimus), Janus kinase (JAK) inhibitors (eg, ruxolitinib), and phosphodiesterase-4 inhibitors (eg, crisaborole) for effective symptom management.

EP: 1.Frontline Management of Atopic Dermatitis in Adults

EP: 2.Considerations for Diagnosis of Atopic Dermatitis in Adults

EP: 3.A Primary Care Perspective on Diagnosing Atopic Dermatitis

EP: 4.Strategies for Determining Severity of Atopic Dermatitis

EP: 5.Collaboration Between Primary Care and Dermatology in Atopic Dermatitis Care

EP: 6.The Utility of Newer Topical Therapies for Atopic Dermatitis

Video content above in prompted by the following:

Have the panelists had exposure to the newer therapeutics, such as topical JAK inhibitors?

Related Videos

3 experts are featured in this series.

Achieving Chronic Spontaneous and Inducible Urticaria Control With Barzolvolimab, with Martin Metz, MD

Scott Commins, MD, PhD I Credit: UNC School of Medicine

Optimizing ISM Treatment Beyond Approval, with Vito Sabato, MBBS

Updated Treatment Strategies for Pediatric Atopic Dermatitis in 2025, with Ama Alexis, MD

Exciting Therapies on the Horizon for Atopic Dermatitis, with Raj Chovatiya, MD, PhD

Faradia Kernizan: Exploring Pediatric Dermatology, Unmet Needs, Mentorship

Jonathan Stine, MD MSc | Credit: AASLD

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.